热门资讯> 正文

Vanda Pharmaceuticals因VGT-1849 B获得FDA孤儿药地位

2025-08-28 22:08

Vanda Pharmaceuticals (NASDAQ:VNDA) said that the U.S. FDA has granted orphan drug designation for its experimental drug candidate, VGT-1849B, for the treatment of polycythemia vera.
With its orphan drug designation, the FDA aims to offer financial incentives to drug developers targeting rare diseases and conditions.
VNDA shares are up 1.5% in morning trade.

More on Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript
Vanda asks FDA's Makary to review approval of Hetlioz generics
Vanda says court ruling opens door for Hetlioz jet lag indication
Seeking Alpha’s Quant Rating on Vanda Pharmaceuticals
Historical earnings data for Vanda Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。